ADVFN US – Market Content Editor

Aclarion Inc. (NASDAQ:ACON) saw its stock rise 6.3% in premarket trading Thursday after announcing that its Nociscan technology will be featured in the Special Pain Issue of the International Journal of Spine Surgery (IJSS). The health tech company, which leverages biomarkers and AI-driven analysis to help clinicians pinpoint the source of chronic low back pain,…

Q/C Technologies (NASDAQ:QCLS) continued its sharp rally on Thursday, climbing another 16% after soaring 38% the previous day. The renewed momentum came after former pharmaceutical executive Martin Shkreli publicly promoted the company as a long investment idea. Shkreli shared his optimistic view of the photonic and optical computing firm on X, setting a short-term price…

Hyperion DeFi Inc. (NASDAQ:HYPD) saw its stock increase 2.2% in premarket trading Thursday after revealing it received nearly 2 million KNTQ tokens through a recent airdrop and continued expanding its network of decentralized finance partnerships. The company confirmed it received exactly 1,918,478.78 KNTQ tokens from the Kinetiq token generation event held on November 27, 2025.…

Estrella Immunopharma Inc. (NASDAQ:ESLA) saw its stock rise 3.1% in premarket trading Thursday after announcing that its CD19-directed cancer therapy has been cleared to move into Phase II clinical testing. The biopharmaceutical company said an independent Data Safety Monitoring Board (DSMB) endorsed advancing the STARLIGHT-1 study into its expansion phase following a positive safety evaluation…

Nayax Ltd. (NASDAQ:NYAX) saw its stock advance 5.1% in premarket trading Thursday after the global payments and commerce enablement firm announced it has acquired Lynkwell, an electric vehicle charging platform enhanced by artificial intelligence. The deal, unanimously approved by both companies’ boards, includes a $25.9 million cash payment for full ownership of the business, along…

Pliant Therapeutics Inc. (NASDAQ:PLRX) saw its stock climb 6.5% in premarket trading Thursday following the release of promising interim findings from a Phase 1 study evaluating its cancer therapy candidate, PLN-101095. The biotech firm, which focuses on clinical-stage drug development, said the investigational treatment showed encouraging anti-tumor effects when used alongside pembrolizumab in patients with…

New data from the Labor Department on Thursday revealed that first-time applications for unemployment benefits in the U.S. declined sharply in the week ending November 29, reaching their lowest point in three years. Initial claims fell to 191,000, down 27,000 from the prior week’s revised total of 218,000. The drop surprised economists, who had been…

Build-A-Bear Workshop, Inc. (NYSE:BBW) posted third-quarter results on Thursday that beat profit forecasts even as tariff-related expenses weighed on margins. The upbeat report sent shares soaring 8.01% in pre-market trading. The company reported earnings per share of $0.62, ahead of analyst expectations of $0.59 but down from $0.73 a year earlier. Revenue came in at…